Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer.

Molina-Arcas M, Moore C, Rana S, van Maldegem F, Mugarza E, Romero-Clavijo P, Herbert E, Horswell S, Li LS, Janes MR, Hancock DC, Downward J.

Sci Transl Med. 2019 Sep 18;11(510). pii: eaaw7999. doi: 10.1126/scitranslmed.aaw7999.

PMID:
31534020
2.

RAC1P29S Induces a Mesenchymal Phenotypic Switch via Serum Response Factor to Promote Melanoma Development and Therapy Resistance.

Lionarons DA, Hancock DC, Rana S, East P, Moore C, Murillo MM, Carvalho J, Spencer-Dene B, Herbert E, Stamp G, Damry D, Calado DP, Rosewell I, Fritsch R, Neubig RR, Molina-Arcas M, Downward J.

Cancer Cell. 2019 Jul 8;36(1):68-83.e9. doi: 10.1016/j.ccell.2019.05.015. Epub 2019 Jun 27.

3.

SHOC2 phosphatase-dependent RAF dimerization mediates resistance to MEK inhibition in RAS-mutant cancers.

Jones GG, Del Río IB, Sari S, Sekerim A, Young LC, Hartig N, Areso Zubiaur I, El-Bahrawy MA, Hynds RE, Lei W, Molina-Arcas M, Downward J, Rodriguez-Viciana P.

Nat Commun. 2019 Jun 10;10(1):2532. doi: 10.1038/s41467-019-10367-x.

4.

Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA.

Coelho MA, de Carné Trécesson S, Rana S, Zecchin D, Moore C, Molina-Arcas M, East P, Spencer-Dene B, Nye E, Barnouin K, Snijders AP, Lai WS, Blackshear PJ, Downward J.

Immunity. 2017 Dec 19;47(6):1083-1099.e6. doi: 10.1016/j.immuni.2017.11.016. Epub 2017 Dec 12.

5.

RAS signalling through PI3-Kinase controls cell migration via modulation of Reelin expression.

Castellano E, Molina-Arcas M, Krygowska AA, East P, Warne P, Nicol A, Downward J.

Nat Commun. 2016 Apr 13;7:11245. doi: 10.1038/ncomms11245.

6.

Hypoxia and P1 receptor activation regulate the high-affinity concentrative adenosine transporter CNT2 in differentiated neuronal PC12 cells.

Medina-Pulido L, Molina-Arcas M, Justicia C, Soriano E, Burgaya F, Planas AM, Pastor-Anglada M.

Biochem J. 2013 Sep 15;454(3):437-45. doi: 10.1042/BJ20130231.

PMID:
23819782
7.

Coordinate direct input of both KRAS and IGF1 receptor to activation of PI3 kinase in KRAS-mutant lung cancer.

Molina-Arcas M, Hancock DC, Sheridan C, Kumar MS, Downward J.

Cancer Discov. 2013 May;3(5):548-63. doi: 10.1158/2159-8290.CD-12-0446. Epub 2013 Mar 1.

8.

Aquaporin 3 (AQP3) participates in the cytotoxic response to nucleoside-derived drugs.

Trigueros-Motos L, Pérez-Torras S, Casado FJ, Molina-Arcas M, Pastor-Anglada M.

BMC Cancer. 2012 Sep 27;12:434. doi: 10.1186/1471-2407-12-434.

9.

Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies.

Steckel M, Molina-Arcas M, Weigelt B, Marani M, Warne PH, Kuznetsov H, Kelly G, Saunders B, Howell M, Downward J, Hancock DC.

Cell Res. 2012 Aug;22(8):1227-45. doi: 10.1038/cr.2012.82. Epub 2012 May 22.

10.

The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer.

Kumar MS, Hancock DC, Molina-Arcas M, Steckel M, East P, Diefenbacher M, Armenteros-Monterroso E, Lassailly F, Matthews N, Nye E, Stamp G, Behrens A, Downward J.

Cell. 2012 Apr 27;149(3):642-55. doi: 10.1016/j.cell.2012.02.059.

11.

How to fool a wonder drug: truncate and dimerize.

Molina-Arcas M, Downward J.

Cancer Cell. 2012 Jan 17;21(1):7-9. doi: 10.1016/j.ccr.2011.12.017.

12.

Role of nucleoside transporters in nucleoside-derived drug sensitivity.

Molina-Arcas M, Pastor-Anglada M.

Nucleosides Nucleotides Nucleic Acids. 2010 Jun;29(4-6):335-46. doi: 10.1080/15257771003729823.

PMID:
20544517
13.

The human concentrative nucleoside transporter-3 C602R variant shows impaired sorting to lipid rafts and altered specificity for nucleoside-derived drugs.

Errasti-Murugarren E, Molina-Arcas M, Casado FJ, Pastor-Anglada M.

Mol Pharmacol. 2010 Aug;78(2):157-65. doi: 10.1124/mol.110.063552. Epub 2010 Apr 26.

PMID:
20421346
14.

Nucleoside transporter proteins.

Molina-Arcas M, Casado FJ, Pastor-Anglada M.

Curr Vasc Pharmacol. 2009 Oct;7(4):426-34. Review.

PMID:
19485885
15.

Transport of lamivudine [(-)-beta-L-2',3'-dideoxy-3'-thiacytidine] and high-affinity interaction of nucleoside reverse transcriptase inhibitors with human organic cation transporters 1, 2, and 3.

Minuesa G, Volk C, Molina-Arcas M, Gorboulev V, Erkizia I, Arndt P, Clotet B, Pastor-Anglada M, Koepsell H, Martinez-Picado J.

J Pharmacol Exp Ther. 2009 Apr;329(1):252-61. doi: 10.1124/jpet.108.146225. Epub 2009 Jan 13. Erratum in: J Pharmacol Exp Ther. 2009 Jun;329(3):1187.

PMID:
19141712
16.

Identification of TIGAR in the equilibrative nucleoside transporter 2-mediated response to fludarabine in chronic lymphocytic leukemia cells.

López-Guerra M, Trigueros-Motos L, Molina-Arcas M, Villamor N, Casado FJ, Montserrat E, Campo E, Colomer D, Pastor-Anglada M.

Haematologica. 2008 Dec;93(12):1843-51. doi: 10.3324/haematol.13186. Epub 2008 Oct 22.

17.

A splice variant of the SLC28A3 gene encodes a novel human concentrative nucleoside transporter-3 (hCNT3) protein localized in the endoplasmic reticulum.

Errasti-Murugarren E, Molina-Arcas M, Casado FJ, Pastor-Anglada M.

FASEB J. 2009 Jan;23(1):172-82. doi: 10.1096/fj.08-113902. Epub 2008 Sep 30.

PMID:
18827020
18.

Physiological and pharmacological roles of nucleoside transporter proteins.

Molina-Arcas M, Trigueros-Motos L, Casado FJ, Pastor-Anglada M.

Nucleosides Nucleotides Nucleic Acids. 2008 Jun;27(6):769-78. doi: 10.1080/15257770802145819. Review.

PMID:
18600539
19.

Compensatory effects of the human nucleoside transporters on the response to nucleoside-derived drugs in breast cancer MCF7 cells.

Cano-Soldado P, Molina-Arcas M, Algueró B, Larráyoz I, Lostao MP, Grandas A, Casado FJ, Pastor-Anglada M.

Biochem Pharmacol. 2008 Feb 1;75(3):639-48. Epub 2007 Oct 13.

PMID:
18053967
20.

Expression and functionality of anti-human immunodeficiency virus and anticancer drug uptake transporters in immune cells.

Minuesa G, Purcet S, Erkizia I, Molina-Arcas M, Bofill M, Izquierdo-Useros N, Casado FJ, Clotet B, Pastor-Anglada M, Martinez-Picado J.

J Pharmacol Exp Ther. 2008 Feb;324(2):558-67. Epub 2007 Nov 27.

PMID:
18042828
21.

3'-Azido-2',3'-dideoxythymidine (zidovudine) uptake mechanisms in T lymphocytes.

Purcet S, Minuesa G, Molina-Arcas M, Erkizia I, Casado FJ, Clotet B, Martinez-Picado J, Pastor-Anglada M.

Antivir Ther. 2006;11(6):803-11.

PMID:
17310825
22.

Human equilibrative nucleoside transporter-1 (hENT1) is required for the transcriptomic response of the nucleoside-derived drug 5'-DFUR in breast cancer MCF7 cells.

Molina-Arcas M, Moreno-Bueno G, Cano-Soldado P, Hernández-Vargas H, Casado FJ, Palacios J, Pastor-Anglada M.

Biochem Pharmacol. 2006 Dec 15;72(12):1646-56. Epub 2006 Sep 11.

PMID:
16965766
23.

Expression of human equilibrative nucleoside transporter 1 (hENT1) and its correlation with gemcitabine uptake and cytotoxicity in mantle cell lymphoma.

Marcé S, Molina-Arcas M, Villamor N, Casado FJ, Campo E, Pastor-Anglada M, Colomer D.

Haematologica. 2006 Jul;91(7):895-902.

24.

Interaction of nucleoside inhibitors of HIV-1 reverse transcriptase with the concentrative nucleoside transporter-1 (SLC28A1).

Cano-Soldado P, Lorráyoz IM, Molina-Arcas M, Casado FJ, Martinez-Picado J, Lostao MP, Pastor-Anglada M.

Antivir Ther. 2004 Dec;9(6):993-1002.

PMID:
15651758
25.

Cell entry and export of nucleoside analogues.

Pastor-Anglada M, Cano-Soldado P, Molina-Arcas M, Lostao MP, Larráyoz I, Martínez-Picado J, Casado FJ.

Virus Res. 2005 Feb;107(2):151-64. Review.

PMID:
15649561
26.

Equilibrative nucleoside transporter-2 (hENT2) protein expression correlates with ex vivo sensitivity to fludarabine in chronic lymphocytic leukemia (CLL) cells.

Molina-Arcas M, Marcé S, Villamor N, Huber-Ruano I, Casado FJ, Bellosillo B, Montserrat E, Gil J, Colomer D, Pastor-Anglada M.

Leukemia. 2005 Jan;19(1):64-8.

PMID:
15510196
27.

Nucleoside transporters in chronic lymphocytic leukaemia.

Pastor-Anglada M, Molina-Arcas M, Casado FJ, Bellosillo B, Colomer D, Gil J.

Leukemia. 2004 Mar;18(3):385-93. Review.

PMID:
14737075
28.

Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 2',2'-difluorodeoxycytidine- induced cytotoxicity.

García-Manteiga J, Molina-Arcas M, Casado FJ, Mazo A, Pastor-Anglada M.

Clin Cancer Res. 2003 Oct 15;9(13):5000-8.

29.

Fludarabine uptake mechanisms in B-cell chronic lymphocytic leukemia.

Molina-Arcas M, Bellosillo B, Casado FJ, Montserrat E, Gil J, Colomer D, Pastor-Anglada M.

Blood. 2003 Mar 15;101(6):2328-34. Epub 2002 Oct 31.

PMID:
12411296

Supplemental Content

Loading ...
Support Center